A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Marginal Zone Lymphoma
Related studies linked through entity extraction aliases.
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- Status
- RECRUITING
- Phase
- N/A
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
B-cell Chronic Lymphoid Malignancies Markers
- Status
- UNKNOWN
- Phase
- N/A
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
- Status
- COMPLETED
- Phase
- N/A
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Status
- RECRUITING
- Phase
- PHASE1
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- Status
- TERMINATED
- Phase
- PHASE3